Displaying items by tag: biotech

(Boston)

Many of the major players in Biotechnology are seeing their stocks soar…see the full story on our partner Magnifi’s site

(Boston)

Most pharmaceutical companies kicked it into high gear to develop the Covid-19 vaccine, but they received very little investor attention…see the full story on our partner Magnifi’s site

(New York)

Vertex Pharmaceuticals was a shining star amongst the already bright biotech industry. In the nearly decade-long stretch…See the full story on our partner Magnifi’s site

(Boston)

The multinational biopharmaceutical company Amgen has agreed to terms to acquire Five Prime Therapeutics Inc. Amgen aims to improve its portfolio of…view the full story on our partner Magnifi’s site

(Washington)

The reality of the political environment in the US is making one thing very clear: it is a tentative time to buy or own healthcare stocks. While healthcare companies are currently performing well, the market is growing increasingly bearish about them, and with good reason. Democratic candidates have proposed an array of new national healthcare plans that all have degrees of disruption, some of them massive, to the status quo. That means the healthcare industry is facing a problem that is very hard to control and could cause extensive changes to their current operating paradigm.

FINSUM: Unless healthcare gets so beat up that it is worth taking a risk on the stocks just as a bet that the Democrats don’t win the election, it seems like there is asymmetric risk reward in the sector right now.